Bronchoscopic Interventions: Stenting, Ablation, and Valve Placement

Bronchoscopic interventional procedures extend the diagnostic scope of standard bronchoscopy into active structural and functional treatment of airway and lung disease. Stenting, ablation, and endobronchial valve placement each address distinct clinical problems — airway obstruction, tumor burden, and hyperinflation — using instruments delivered through a flexible or rigid bronchoscope. Understanding the mechanics, indications, and procedural boundaries of these techniques is essential context for patients navigating advanced pulmonary disease and for clinicians coordinating multidisciplinary care decisions.

Definition and Scope

Bronchoscopic interventions constitute a subspecialty domain within interventional pulmonology, a field recognized by the American College of Chest Physicians (ACCP) and overseen in practice by fellowship-trained specialists (see Interventional Pulmonology Fellowship). These procedures share a common access route — the bronchoscope passed through the mouth or nose into the tracheobronchial tree — but diverge sharply in mechanism and target pathology.

The three principal categories are:

1. Airway stenting — placement of a tubular prosthesis to maintain patency of a narrowed or collapsing airway
2. Ablative techniques — destruction or debulking of tissue obstructing the bronchial lumen, using thermal, photodynamic, or mechanical energy
3. Endobronchial valve placement — one-way valve insertion to redirect airflow and reduce hyperinflation in emphysematous lung segments

The regulatory context for pulmonary procedures is shaped by FDA device-clearance requirements, since all three categories involve implantable or energy-delivery devices subject to 510(k) or premarket approval review under 21 CFR Part 807 and Part 814 respectively.

How It Works

Airway Stenting

Stents are deployed under bronchoscopic and often concurrent fluoroscopic guidance. Two broad stent classes exist:

• Silicone stents (e.g., Dumon-type): require rigid bronchoscopy for placement; repositionable and removable; lower mucosal ingrowth risk
• Self-expanding metallic stents (SEMS): deployable via flexible bronchoscope; conform readily to irregular anatomy; higher risk of tissue ingrowth over time, complicating removal

The FDA cleared the Dumon silicone stent system and multiple SEMS configurations under 510(k) pathways. Stent diameter selection is guided by airway measurement — tracheal stents typically range from 12 mm to 20 mm in diameter, while bronchial stents commonly span 8 mm to 14 mm.

Ablative Techniques

Ablation targets endoluminal or submucosal tissue. The primary modalities include:

• Electrocautery and argon plasma coagulation (APC): electrical current delivered via probe or non-contact argon gas beam; rapid debulking of friable endobronchial tumor; depth of effect approximately 2–3 mm for APC
• Nd:YAG laser: 1064 nm wavelength penetrates 4–6 mm; used for vascular tumors and fibrotic stenoses; requires eye protection and fire precautions per ANSI Z136.3 laser safety standards
• Photodynamic therapy (PDT): systemic photosensitizer (porfimer sodium, FDA-approved under NDA 020451) activated by 630 nm light; necrosis develops over 48–72 hours; indicated for early-stage central airway carcinomas and palliation
• Cryotherapy: freezing (-89°C with nitrous oxide probes) causes delayed tissue necrosis; lower immediate hemostatic control but useful for submucosal disease

Endobronchial Valve Placement

The Zephyr Endobronchial Valve (Pulmonx) received FDA approval in 2018 under PMA P180002 for patients with severe heterogeneous emphysema and intact interlobar fissures. Valves are placed in subsegmental bronchi feeding the most diseased lobe; one-way design allows exhalation while blocking inhalation, inducing lobar atelectasis and functional volume reduction. The LIBERATE trial, which supported FDA approval, demonstrated a 14.6% improvement in FEV₁ at 12 months in the treatment arm versus 2.8% in the control arm (FDA Summary of Safety and Effectiveness, P180002).

Common Scenarios

Bronchoscopic interventions are applied across a defined set of clinical presentations:

• Malignant central airway obstruction (MCAO): lung cancer, esophageal cancer, or mediastinal lymphadenopathy compressing the trachea or mainstem bronchi; stenting or ablation restores luminal patency, frequently enabling continuation of systemic therapy
• Benign airway stenosis: post-intubation tracheal stenosis (occurring in an estimated 1%–2% of mechanically ventilated patients per published ICU outcome literature) and post-transplant bronchial anastomotic stenosis; silicone stenting or balloon dilation with cryotherapy are preferred
• Endobronchial carcinoid or granuloma tissue: electrocautery or cryotherapy for controlled debulking under direct vision
• Advanced emphysema with lobar hyperinflation: valve placement in patients meeting LIBERATE-trial inclusion criteria (FEV₁ 15%–45% predicted, RV ≥ 175% predicted, intact fissure on CT)
• Tracheobronchomalacia: dynamic airway collapse managed with silicone Y-stents spanning the carina when surgical tracheoplasty is not feasible

Decision Boundaries

Patient selection for bronchoscopic intervention is not uniform across techniques. The ACCP and the American Association for Bronchology and Interventional Pulmonology (AABIP) publish evidence-based guidelines that define procedural candidacy.

Key decision criteria include:

1. Performance status: Eastern Cooperative Oncology Group (ECOG) score ≥ 3 generally precludes elective bronchoscopic procedures in malignant contexts
2. Fissure integrity: Zephyr valve placement requires ≥ 95% fissure completeness on high-resolution CT; collateral ventilation testing with the Chartis system (Pulmonx) provides additional physiological confirmation
3. Bleeding risk: platelet count < 50,000/µL or INR > 1.5 requires correction before laser or electrocautery procedures per published anesthesia and bronchoscopy society guidance
4. Stent type selection: removability is the decisive factor — benign disease mandates a retrievable stent (silicone preferred); malignant disease with limited prognosis may tolerate SEMS despite ingrowth risk
5. Multidisciplinary review: ACCP guidelines recommend tumor board or equivalent review before stenting in MCAO to align intervention with systemic oncologic strategy

The broader landscape of interventional options — including surgery and lung transplant — is covered within the main pulmonary overview, contextualizing where bronchoscopic procedures fit within the full treatment continuum.

References

• FDA Premarket Approval P180002 — Zephyr Endobronchial Valve
• FDA 21 CFR Part 807 — Premarket Notification (510(k))
• FDA 21 CFR Part 814 — Premarket Approval
• American College of Chest Physicians (ACCP)
• American Association for Bronchology and Interventional Pulmonology (AABIP)
• ANSI Z136.3 — American National Standard for Safe Use of Lasers in Health Care
• FDA Drug Approval NDA 020451 — Porfimer Sodium (Photofrin)

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)